Many children with diabetes require small doses of insulin administered with syringes or pen-injector devices (at the Booth Hall Paediatric Diabetic Clinic, 20% of children aged 0–5 years receive 1–2 U insulin doses). To determine how accurately and reproducibly small doses are delivered, 1, 2, 5, and 10 U doses of soluble insulin (100 U/ml) were dispensed in random order 15 times from five new NovoPens (1.5 ml), five BD-Pens (1.5 ml), and by five nurses using 30 U syringes. Each dose was weighed, and intended and actual doses compared. The two pen-injectors delivered less insulin than syringes, differences being inversely proportional to dose. For 1 U (mean (SD)): 0.89 (0.04) U (NovoPen), 0.92 (0.03) U (BD-Pen), 1.23 (0.09) U (syringe); and for 10 U: 9.8 (0.1) U (NovoPen), 9.9 (0.1) U (BD-Pen), 10.1 (0.1) U (syringe). The accuracy (percentage errors) of the pen-injectors was similar and more accurate than syringes delivering 1, 2, and 5 U of insulin. Errors for 1 U: 11(4)% (NovoPen), 8(3)% (BD-Pen), 23(9)% (syringe). The reproducibility (coefficient of variation) of actual doses was similar (< 7%) for all three devices, which were equally consistent at underdosing (pen-injectors) or overdosing (syringes) insulin. All three devices, especially syringes, are unacceptably inaccurate when delivering 1 U doses of insulin. Patients on low doses need to be educated that their dose may alter when they transfer from one device to another.
Insulin doses of < 2 U are administered inaccurately by syringe and pen-injector devices
The reproducibility (coefficient of variation) of actual doses was similar (< 7%) using two pen-injector devices (NovoPen and BD-Pen), and 30 U syringes
Pen-injectors underdose and nurses using 30 U syringes overdose insulin
Transferring patients on low insulin doses from syringe to pen-injector may result in a significant dose change
- pen-injector device
- insulin syringes
- insulin administration
- low dose insulin
Statistics from Altmetric.com
In 1983, U100/ml insulin was introduced and the more dilute U40/ml and U80/ml insulins were withdrawn in the UK. This simplified treatment and reduced the potential for dosage errors, but it also resulted in small doses of insulin being dispensed in extremely small volumes (1 U = 0.01 ml). Many children require small doses and these may be administered using a variety of pen-injector devices or different sized syringes. It is obviously important that small doses are administered accurately, and that the magnitude of potential dosage error is appreciated. Furthermore, because patients may change from using syringes to pen-injectors, any differences in dosage accuracy and precision using these devices should be recognised.
The limitations of professionals and patients attempting to draw up small doses of insulin into syringes are well recognised,1 2 inaccuracies being inversely proportional to the prescribed dose of insulin.1 Casellaet al concluded that insulin injections of less than 20 μl (2 U of U100) administered by syringe had an unacceptably large error.2 Similar information about pen-injector devices is not readily available, although one report found that the NovoPen 1 delivered 2 U very accurately.3
To establish a policy for the administration of small doses of insulin, we compared the accuracy and reproducibility of administering small doses of insulin using two pen-injector devices and 30 U insulin syringes.
To determine how frequently children require insulin doses of ⩽ 5 U, the insulin regimen and individual doses used by children attending the Booth Hall Paediatric Diabetic Clinic were collected from their last outpatient visit. The children’s age, sex, and duration of disease were recorded, and the device used (pen-injector or syringe) for insulin injection was noted.
To determine how accurately and reproducibly two pen-injector devices deliver small doses of insulin, five new NovoPens (1.5 ml) (NovoNordisk Pharmaceuticals) and five new BD-Pens (1.5 ml) (Becton Dickinson, Oxford, UK) with 29 G needles (BD microfine) were used to deliver Humulin S (Eli Lilly, Basingstoke, Hants, UK) and Human Actrapid (NovoNordisk Pharmaceuticals, Crawley, West Sussex, UK) insulin, respectively. The 1.5 ml insulin cartridges (100 U/ml) were left at room temperature for two hours before use. Before the sequence of measurements was made from each cartridge, an “air shot” was performed and 5 U insulin was wasted. From each pen, 1, 2, 5, and 10 U doses were expelled in random order 15 times, and the mean was used in subsequent analyses. All measurements were performed by a single investigator (MG) who waited 10 seconds after depressing the plunger each time to ensure that all the dialled dose was expelled. Each dose of insulin was deposited onto a polystyrene weighing container and was weighed immediately using an analytical balance (Avery Berkel FA214 balance; Avery Berkel Ltd, Shirley Institute, Manchester, UK) which has an accuracy of 0.0001 g and a reproducibility of ⩽ ± 0.0001 g. The balance has an autocalibration facility, and was zeroed before the next dose of insulin was deposited and weighed.
For comparison, five paediatric nurses who regularly administered insulin, used 30 U insulin syringes with 29 G needles (BD microfine) to draw up the same doses (1, 2, 5, and 10 U) of soluble insulin (100 U/ml) in random order 15 times. The vials of insulin were left at room temperature for two hours before use. Individual doses were expelled and weighed as previously described and the nurses were unable to view the results.
To study the pen-injector devices further, we considered whether the device or the insulin cartridge was the main source of any error. The BD-Pen and the NovoPen that had the lowest percentage error during the initial experiment were selected for further study. Following appropriate air shots, 5 U of soluble insulin were dispensed and measured repeatedly until each insulin cartridge was emptied. Measurements were made using five cartridges of Humulin S and Human Actrapid insulin in the BD-Pen and NovoPen, respectively. For the purposes of analysis, each cartridge was divided into first, second, third, and fourth quarters, and there was an average of seven measurements from each of the quarters.
To validate the methodology that formed the basis of this study, 10 μl of distilled water or 10 μl of soluble insulin was dispensed 15 times using a laboratory pipette (10 μl Gilson Microman Bio-pipette; Villiers-le-bel, France) and was weighed as described previously. Aliquots of water had a mean (SD) weight of 0.01001 (0.00027) g and insulin samples weighed 0.00963 (0.00021) g. The coefficient of variation for the method was < 3%, and for the purposes of this study it was assumed that 10 U of insulin (10 μl) weighed 0.01 g.
Dose accuracy and reproducibility were defined as follows:
All results were presented as means (SD) unless otherwise stated. Data were analysed by two factor anova to determine population differences and by post hoc Duncan’s multiple range test to detect intergroup variation. The interaction term states the relation between the device used and the intended dose of insulin. A probability of < 0.05 was considered significant.
One hundred and twelve children (64 boys and 48 girls) attended the clinic. Their mean (SD) age was 11.51 (4.21) years and duration of disease 4.48 (3.52) years. Insulin was administered twice daily (101 children), once daily (seven children) or four times daily (three children). One girl who had autoimmune enteropathy received subcutaneous insulin once daily and insulin by intravenous infusion overnight while she received total parenteral nutrition. Twenty six of the 112 children were administered one or more doses of 1–5 U insulin and the other five received one or more doses of only 1–2 U. Of 15 children aged 0–5 years, three were receiving doses of only 1–2 U. Pen-injector devices were used by 101 children and appropriately sized insulin syringes by the other 11 children. Only one child was receiving self mixed insulin.
Table 1 shows the intended and actual doses of insulin delivered by the pen-injectors and syringes. The two pen-injector devices delivered significantly less insulin than did experienced nurses using 30 U insulin syringes at all doses studied (pen-injectorsv syringes, F = 151, p < 0.0001; units of insulin, F = 58160, p < 0.0001; interaction term, F = 1, p = 0.4). There were no differences in the mean insulin dose delivered by NovoPens and BD-Pens, and both tended to underdose. Nurses using 30 U syringes tended to overdose, particularly when attempting to deliver 1 U (+34% and +38% compared with NovoPens and BD-Pens, respectively) and 2 U (+18% compared with both pen-injectors).
Figure 1 shows the percentage error (accuracy) and coefficient of variation (reproducibility) with which the pen-injector devices and 30 U syringes delivered small doses of insulin. Over the dose range studied, both pen-injector devices performed similarly and had lower percentage errors overall than nurses using 30 U syringes (pen-injectors v syringes, F = 130, p < 0.0001). For 1, 2, and 5 U insulin doses, the percentage error using syringes was greater than with the NovoPen and BD-Pen (p < 0.01). With all three devices, the percentage error diminished with increasing doses of insulin: 1 > 2 > 5 ∼ 10 U (units of insulin, F = 1.6, p < 0.2; interaction term, F = 29, p < 0.0001).
Figure 1B shows how reproducibly small doses of insulin can be delivered using the three devices, regardless of their accuracy. The coefficient of variation was similar for both pen-injector devices and for the 30 U insulin syringes (F = 0.5, p = 0.6) —that is, they were equally consistent at under or overadministering insulin. With all three devices, the coefficient of variation diminished with increasing doses of insulin: 1 > 2 > 5 ∼ 10 U (F = 52, p < 0.0001; interaction term, F = 0.4, p = 0.9).
There were no differences in the 5 U doses of insulin delivered from the four quarters of the cartridges in the NovoPens and BD-Pens (F = 0.42, p = 0.7) (results not shown).
This is the first study to compare the accuracy and reproducibility of pen-injectors and syringes delivering small doses of insulin. Previous studies have shown that delivering small doses of insulin using 30, 50, and 100 U syringes is extremely inaccurate and imprecise with a human bias towards over- administration.1 2 Casellaet al reported that paediatric nurses attempting to deliver 0.5, 1.0, and 2.0 U insulin resulted in delivered doses of 0.975 (0.315), 1.638 (0.376), and 2.153 (0.435) U, respectively2; an overdose of 95%, 64%, and 7.5%, respectively. They concluded that insulin injections of less than 20 μl (2 U of U100/ml) had an unacceptably large error when administered by syringe. Our results concurred with this, the percentage errors of paediatric nurses drawing up 1 U and 2 U doses using 30 U insulin syringes being 23% and 12%, respectively. It is interesting that parents could draw up insulin more accurately than the nurses could.2 Bell et alreported much higher percentage errors (45% for 2 U, 20% for 5 U) probably because their study involved self mixing regular and isophane insulins, which were shown to be far less accurate, and the participants were not allowed to overdraw the syringe and evacuate the excess.1 Disappointingly, use of the narrower bore 30 U syringe instead of 50 U and 100 U syringes did not improve the accuracy or precision of professionals,1 2 but in patients there was a small but significant improvement at low doses.2 Because 30 U syringes were better or certainly no worse at delivering small doses, we confined ourselves to the 30 U syringe in this study.
Information about the accuracy and precision of pen-injector devices delivering small doses is not readily available, although Gordon and colleagues3 reported that the accuracy of NovoPen 1 delivering 2 U was good, having a percentage error of 2.8%. This compares with percentage errors of 5.1% for 2 U doses administered using the NovoPen 1.5 or the BD-Pen 1.5 in our study. Our results demonstrated that the accuracy and reproducibility of the NovoPens and BD-Pens were similar and both improved as the dose increased. Both pen-injectors were significantly more accurate than 30 U insulin syringes at doses of 1, 2, and 5 U but, perhaps surprisingly, the variability of actual doses administered was very similar between the pen devices and syringes. Our results demonstrated that when using syringes there was a human bias towards overdosage while pen-injector devices tended to underdose. This is important if one is considering transferring patients from syringe to pen or vice versa. An intended dose of 1 U may be an actual dose of 0.89 U by pen or 1.23 U by syringe, so changing from one device to the other would amount to a change in dose of 38%.
This study reflects favourably on pen-injector devices in terms of their accuracy, and the BD-Pen and NovoPen were equally good. It must be remembered, however, that there are numerous opportunities to introduce error when using such devices in clinical practice—for example, when patients do not remove the needle between injections or do not do an air shot before injecting.4 Also, insulin is delivered more slowly from cartridges than syringes because of the compressible elements of the cartridge.4 If patients fail to leave the needle in place for the recommended five or 10 seconds after pushing down the plunger (when using 12.7 mm 29 G or 8 mm 30 G needles, respectively), they may administer less insulin than intended.
We tried to determine whether the devices or the insulin cartridges were the most important source of error for the pen-injectors. By comparing the doses delivered from the four quarters of the cartridge, we attempted to detect errors created by defects in the glass cylinders that make up the cartridges. No differences were found between the doses delivered from the different parts of the cartridge, but we acknowledge that we used fairly crude methodology. Becton Dickinson informed us that the glass cartridges were probably the most important source of dosage variability (personal communication).
Added to the considerable inaccuracies and variability involved in administering small volumes of insulin, there are many other factors that affect the absorption and hence the activity profile of insulin. The reported intraindividual and interindividual variation of absorption is about 25% and 50%, respectively,5 6 and children are at high risk of receiving inadvertent intramuscular injections,7 8 which leads to faster absorption.9 10
In conclusion, administering small volumes of insulin is fraught with problems, and yet in this study 20% of children aged 0–5 years were receiving doses of 1–2 U (10–20 μl of U100/ml). The incidence of diabetes in children aged 0–4 years is increasing by 11% per year11 at a time when we know we should strive for normoglycaemia.12 However, tight control results in a significant risk of severe hypoglycaemia,12 which is potentially more harmful in this age group.13 Any dosing error will increase this risk and so perhaps we should consider requesting the reinstatement of the more dilute U40 insulin, which is still available in some countries. This would enable parents to deliver small doses more accurately and precisely. Alternatively, we should consider giving once rather than twice daily injections to children whose evening dose is less than 2 U, and possibly to those receiving 2 U doses.
We are grateful to Sue Bennett (diabetes specialist nurse) and Franscine Radivan (senior pharmacist) for their help; as well as to Eli Lilly and Co and Novo Nordisk Pharmaceuticals Ltd for supplying the insulin.